Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Metastatic Melanoma Clinical Trial

Official title:

A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00984464
• Other study ID #: REO 020
• Status: Completed
• Phase: Phase 2
• First received: September 24, 2009
• Last updated: April 8, 2015
• Start date: September 2009
• Est. completion date: October 2014

Study information

• Verified date: April 2015
• Source: Oncolytics Biotech
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.

Description:

Cutaneous melanoma is one of the most rapidly increasing cancers in the US and around the world with an increase in incidence of about 3-7% per year for fair-skinned Caucasian populations. An estimated 62,480 cases of invasive melanoma will be diagnosed in the US in 2008 with an estimated 8,420 deaths. An additional 46,170 cases of melanoma in situ are predicted.

Melanoma that has spread to distant sites (stage IV) is rarely curable.

This Phase 2 study is designed to characterize the efficacy and safety of REOLYSIN given intravenously in combination with paclitaxel and carboplatin every 3 weeks in patients with metastatic melanoma.

Response is a primary endpoint of this trial.

Patients may continue to receive chemotherapy in combination with REOLYSIN for up to 8 cycles and may continue indefinitely on REOLYSIN monotherapy under this protocol, provided they have not experienced either progressive disease or unacceptable drug-related toxicity that does not respond to either supportive care or dose reduction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: October 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• have histologically or cytologically confirmed metastatic malignant melanoma.

• have measurable disease.

• have failed at least one prior treatment for metastatic disease or not considered a candidate for standard first line treatment.

• have not received previous carboplatin and/or paclitaxel chemotherapy.

• have NO continuing acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures.

• any surgery involving the melanoma (except biopsies) must have occurred at least 28 days prior to study enrolment.

• be at least 18 years of age.

• have received NO chemotherapy, radiotherapy, immunotherapy or hormonal therapy within 28 days prior to receiving study drug

• have ECOG Performance Score of = 2.

• have a life expectancy of at least 3 months.

• absolute neutrophil = 1.5 x 10^9; Platelets = 100 x10^9; Hemoglobin = 9.0 g/dL; Serum creatinine = 1.5 x upper limit of normal (ULN); Bilirubin = 1.5 x ULN; AST/ALT = 2.5 x ULN.

• negative pregnancy test for females with childbearing potential.

• be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests.

Exclusion Criteria:

• receive concurrent therapy with any other investigational anticancer agent while on study.

• be good candidate for surgery with curative intent for metastatic disease.

• have a history of or current evidence of brain metastasis(es).

• be on immunosuppressive therapy or have known HIV infection or active hepatitis B or C.

• be a pregnant or breast-feeding woman.

• have clinically significant cardiac disease.

• have dementia or altered mental status that would prohibit informed consent.

• have any other acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Biological:
• REOLYSIN
3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle

Drug:
• Carboplatin
6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
• Paclitaxel
200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle

Locations

Country	Name	City	State
United States	Cancer Therapy & Research Center at UTHSCSA	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Oncolytics Biotech	University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the antitumor effect in terms of objective response rates (i.e., partial response (PR) and complete response (CR) to treatment)		must be confirmed 4 weeks after the criteria for response are first met.	No
Secondary	Evaluate the safety and tolerability of the treatment regimen in the study population.		Within 30 days of last dose of REOLYSIN	Yes
Secondary	Assess progression-free survival (PFS) and overall survival (OS) and disease control [CR+PR+Stable Disease (SD)] rate and duration in the study population		until death	No